Health Condition 1: null- Adenoviral Conjunctivitis Health Condition 2: H108- Other conjunctivitis
Conditions
Interventions
Intervention1: SHP640 (0.1% Dexamethasone and 0.6% PVP-I) Ophthalmic Suspension.
: 1 drop of investigational product in each eye 4 times daily (with a minimum of 2 hours between doses) for 7 days.
Co
Sponsors
Shire Pharmaceuticals Ltd
Shire Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. An understanding, ability, and willingness to fully comply with study procedures and restrictions (by the parent(s), guardian, or legally authorized representative, if applicable). 2. Ability to voluntarily provide written, signed, and dated (personally or via a parent(s), guardian, or legally-authorized representative(s) informed consent (and assent, if applicable) to participate in the study. 3. Subjects of any age at Visit 1 (Note: subjects =37 weeks gestational age at birth). 4. Have a positive AdenoPlus® test at Visit 1 in at least 1 eye. 5. Have a clinical diagnosis of suspected adenoviral conjunctivitis in at least 1 eye (the sameeye as the AdenoPlus positive eye) confirmed by the presence of the following minimalclinical signs and symptoms in that same eye: -Report presence of signs and/or symptoms of adenoviral conjunctivitis for -Bulbar conjunctival injection: a grade of >=1 on 0-4 scale of Bulbar Conjunctival Injection Scale - Watery conjunctival discharge: a grade of >=1 (mild) on a 0-3 Watery Conjunctival Discharge Scale 6. Be willing to discontinue contact lens wear for the duration of the study. 7. Have a Best Corrected Visual Acuity (BCVA) of 0.60 logMAR or better in each eye as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. BCVA will be assessed by an age appropriate method in accordance with the AAP Policy Statement for Visual System Assessment in Infants, Children, and Young Adults by Pediatricians (Donahue and Baker, 2016; American Academy of Pediatrics, 2016). The policy statement recommends formal vision screening can begin at 3 years of age. VA measurements for children under the age of 3 will be done at the discretion of the investigator. If not done, child should be able to fixate on and follow a moving object, except subjects 8. Male, or non-pregnant, non-lactating female who agrees to comply with any applicable contraceptive requirements of the protocol or females of non-childbearing potential
Exclusion criteria
Exclusion criteria: 1. Current or recurrent disease that could affect the action, absorption, or disposition of the investigational product, or clinical or laboratory assessments, per investigatorâ??s discretion. 2. Current or relevant history of physical or psychiatric illness, any medical disorder that may make the subject unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures. 3. Have known or suspected intolerance or hypersensitivity to the investigational product, closely related compounds, or any of the stated ingredients 4. Prior enrollment in a FST-100 or SHP640 clinical study. 5. Subjects who are employees, or immediate family members of employees (who are directly related to study conduct), at the investigational site. 6. Have a history of ocular surgical intervention within 7. Have a preplanned overnight hospitalization during the period of the study. 8. Have presence of any intraocular, corneal, or conjunctival ocular inflammation (eg, uveitis, iritis, ulcerative keratitis, chronic blepharoconjunctivitis), other than adenoviral conjunctivitis. 9. Have presence of corneal subepithelial infiltrates at Visit 1 10. Have active or history of ocular herpes. 11. Have at enrollment or within 12. Neonates or infants (ie. subjects less than 12 months of age) who have suspected or confirmed (based on the result of any test conducted prior to screening) conjunctivitis of gonococcal, chlamydial, herpetic or chemical origin. 13. Neonates or infants (ie. subjects less than 12 months of age) whose birth mothers had any sexually transmitted disease within 1 month of delivery or any history of genital herpes. 14. Presence of nasolacrimal duct obstruction at Visit 1 (Day 1). 15. Presence of any significant ophthalmic condition (eg, Retinopathy of Prematurity, congenital cataract, congenital glaucoma) or other congenital disorder with ophthalmic involvement that could affect study variables. 16. Be a known intraocular pressure (IOP) steroid responder, have a known history of glaucoma,be a glaucoma suspect, or have a known history of an elevated IOP > 21 mmHg. 17. Have any known clinically significant optic nerve defects. 18. Have a history of recurrent corneal erosion syndrome, either idiopathic or secondary to previous corneal trauma or dry eye syndrome; presence of corneal epithelial defect or any significant corneal opacity at Visit 1. 19. Presence of significant, active condition in the posterior segment which requires invasive treatment (eg, intravitreal treatment with VEGF inhibitors or corticosteroids) and may progress during the study participation period. 20. Have used any topical ocular or systemic anti-virals or antibiotics within 21. Have used any topical ocular NSAIDs within 22. Have used any topical ophthalmic steroids in the last 23. Have used any systemic corticosteroid agents within =30 days prior to enrollment) use of inhaled and nas
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of this study is to evaluate the efficacy of SHP640 based on clinical resolution (defined as absence of bulbar conjunctival injection and watery conjunctival discharge) compared with placebo in the treatment of subjects with adenoviral conjunctivitis in the study eye at Visit 3 (Day 6).Timepoint: The primary objective of this study is to evaluate the efficacy of SHP640 based on clinical resolution (defined as absence of bulbar conjunctival injection and watery conjunctival discharge) compared with placebo in the treatment of subjects with adenoviral conjunctivitis in the study eye at Visit 3 (Day 6). | — |
Secondary
| Measure | Time frame |
|---|---|
| Adenoviral eradication as assessed by CC-IFA at Visits 4 (Day 8) and 5 (Day 12) Timepoint: Visits 4 (Day 8) and 5 (Day 12);Adenovirus viral titer assessed by quantitative polymerase chain reaction (qPCR) at Visit 3 (Day 6) and 4 (Day 8)Visit 3 (Day 6) and 4 (Day 8)Timepoint: Visit 3 (Day 6) and 4 (Day 8)Visit 3 (Day 6) and 4 (Day 8);Clinical resolution of adenoviral conjunctivitis at Visits 2 (Day 3), 4 (Day 8) and 5 (Day 12)Timepoint: Visits 2 (Day 3), 4 (Day 8) and 5 (Day 12);Expanded clinical resolution, defined as a global clinical score of 0, 1, or 2 with neither injection nor discharge having a score of 2, at Visits 2 (Day 3), 3 (Day 6), 4 (Day 8) and 5 (Day 12Timepoint: Visits 2 (Day 3), 3 (Day 6), 4 (Day 8) and 5 (Day 12;Individual clinical signs (bulbar conjunctival injection and watery conjunctival discharge) at Visits 2 (Day 3), 3 (Day 6), 4 (Day 8) and 5 (Day 12).Timepoint: Visits 2 (Day 3), 3 (Day 6), 4 (Day 8) and 5 (Day 12).;Modified clinical resolution, defined as a global clinical score of 0 or 1, at Visits 2 (Day 3), 3 (Day 6), 4 (Day 8) and 5 (Day 12)Timepoint: Visits 2 (Day 3), 3 (Day 6), 4 (Day 8) and 5 (Day 12);The global clinical score (sum of bulbar conjunctival injection and watery conjunctival discharge) and change from baseline in the global clinical score at Visits 2 (Day 3), 3 (Day 6), 4 (Day 8) and 5 (Day 12).Timepoint: Visits 2 (Day 3), 3 (Day 6), 4 (Day 8) and 5 (Day 12).;Time to clinical resolution based upon assessments at Visits 2 (Day 3), 3 (Day 6), 4 (Day 8), and 5 (Day 12)Timepoint: Visits 2 (Day 3), 3 (Day 6), 4 (Day 8), and 5 (Day 12);To assess the status of cross-over infection (as assessed by CC-IFA) to a subjectâ??s fellow eye at Visits 2 (Day 3), 3 (Day 6), 4 (Day 8) and 5 (Day 12) for subjects with only 1 infected eye at baselineTimepoint: Visits 2 (Day 3), 3 (Day 6), 4 (Day 8) and 5 (Day 12);To evaluate the efficacy of PVP-I based on adenoviral eradication (defined as negative cell culture-immunofluorescence assay [CC- | — |
Countries
Australia, Austria, Canada, Colombia, Estonia, France, Germany, Hungary, India, Israel, Italy, Other, Peru, Philippines, Poland, South Africa, Spain, United Kingdom, United States of America
Contacts
Public ContactDr. Bhaskar Jyoti Sonowal
Baxalta Bioscience India Pvt. Ltd. Now Part of Shire
Outcome results
None listed